-+ 0.00%
-+ 0.00%
-+ 0.00%

Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension

PUBT·06/23/2026 11:51:53
Listen to the news
Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension
  • Galectin Therapeutics reported FDA Type C meeting alignment to advance belapectin into a Phase 3 trial for MASH cirrhosis with portal hypertension.
  • No new clinical results were presented; the update outlines a future registration-focused study intended to support a full approval filing.
  • The planned trial targets prevention of disease progression, using a composite clinical outcome that includes avoiding development of large esophageal varices.
  • FDA accepted the blinded central endoscopy review approach, supporting consistency of key assessments across sites.
  • Protocol submission is planned for Q3 2026; the company is pursuing strategic or financial partners to fund development and commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-026031), on June 23, 2026, and is solely responsible for the information contained therein.